Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have earned an average recommendation of “Hold” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $5.25.

MRVI has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Wells Fargo & Company increased their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th.

Insider Buying and Selling at Maravai LifeSciences

In related news, Director Gregory T. Lucier bought 48,528 shares of the business’s stock in a transaction on Monday, December 8th. The shares were bought at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the purchase, the director owned 155,123 shares of the company’s stock, valued at $569,301.41. This represents a 45.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bernd Brust purchased 216,212 shares of the stock in a transaction dated Thursday, November 13th. The shares were purchased at an average price of $3.25 per share, with a total value of $702,689.00. Following the transaction, the chief executive officer directly owned 466,771 shares of the company’s stock, valued at approximately $1,517,005.75. The trade was a 86.29% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 566,771 shares of company stock worth $1,880,244 over the last ninety days. 2.11% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maravai LifeSciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Callan Family Office LLC acquired a new position in Maravai LifeSciences during the 2nd quarter worth $25,000. Ethic Inc. acquired a new position in shares of Maravai LifeSciences during the second quarter valued at $26,000. Sprott Inc. bought a new stake in shares of Maravai LifeSciences during the third quarter valued at about $29,000. Quantessence Capital LLC acquired a new stake in Maravai LifeSciences in the third quarter worth about $31,000. Finally, Abel Hall LLC acquired a new stake in Maravai LifeSciences in the third quarter worth about $33,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Stock Down 4.3%

MRVI stock opened at $3.75 on Wednesday. The firm has a market cap of $958.91 million, a price-to-earnings ratio of -4.46 and a beta of 0.33. Maravai LifeSciences has a 1-year low of $1.66 and a 1-year high of $6.05. The firm has a fifty day moving average price of $3.59 and a two-hundred day moving average price of $3.05. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The business had revenue of $41.63 million during the quarter, compared to the consensus estimate of $49.02 million. Research analysts predict that Maravai LifeSciences will post -0.24 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.